Ascentage Pharma Group International (HK:6855) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The phase II study “A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma” is testing Ascentage Pharma’s lead blood cancer drug in hard-to-treat CLL/SLL. It aims to show if the drug works well enough and is safe enough to support a future marketing submission.
The trial is evaluating APG-2575, an oral cancer pill taken once a day in 28 day cycles. It is designed to help patients whose CLL or SLL has come back or no longer responds to prior treatments, a group with limited options and high unmet need.
This is an interventional phase II trial using a single treatment group, so all enrolled patients receive APG-2575 and there is no placebo or active comparison arm. There is no blinding, which means doctors and patients know they are getting the drug, and the main goal is to test treatment benefit rather than prevention or diagnosis.
The study was first submitted in late November 2021, marking the start of its clinical journey in relapsed or refractory CLL/SLL. The most recent update was filed on March 24, 2026, signaling that the trial is active, data collection continues, and the sponsor is keeping regulators and investors informed.
Investors in Ascentage Pharma (6855) may view this update as a sign that a pivotal asset is moving steadily through development, which can support long term value if data prove competitive versus existing CLL drugs like AbbVie’s venetoclax. Near term share moves will likely track news on response rates and safety, and positive interim signals could lift sector sentiment for smaller oncology developers.
The study remains ongoing and recently updated, with additional operational and clinical details available on the ClinicalTrials.gov portal under the listed registration number.
To learn more about HK:6855’s potential, visit the Ascentage Pharma Group International drug pipeline page.